Feasibility of conducting a pilot randomized control trial of a psycho-education intervention in patients with a first episode psychosis in Uganda-A study protocol

Dickens Akena, Aggrey Semeere, Philippa Kadama, Emmanuel K Mwesiga, Juliet Nakku, Noeline Nakasujja, Dickens Akena, Aggrey Semeere, Philippa Kadama, Emmanuel K Mwesiga, Juliet Nakku, Noeline Nakasujja

Abstract

Background: Psychotic disorders contribute to significant morbidity and mortality partly due to the chronicity of the illness and high relapse rates. Delivering psycho-education messages about disease etiology, their signs and symptoms and the benefits of treatment adherence have been shown to improve clinical outcomes among individuals with psychoses. However, little has been done to examine the feasibility and efficacy of this intervention in low resourced settings.

Objective: Our primary objective will be to determine the feasibility of recruiting and retaining patients with a first episode psychosis (FEP) and for the secondary objective, we will determine the preliminary efficacy of psycho-education on illness self-management, stigma, adherence to medications and symptom severity.

Hypothesis: We hypothesize that (i) we will recruit 70% of eligible participants and accrue a sample size of 80 over 20-weeks, retaining 80% of the sample size for 24 weeks, (ii) the intervention will lead to improvement in clinical outcomes (described above).

Methods: We will recruit 80 adult patients who have been diagnosed with a FEP, received antipsychotic medication at Butabika Hospital and reside within 21km from the Hospital. Trained village health team (VHTs) members will deliver 6 psycho-education sessions to 40 participants and their family members (intervention arm). Participants in the control arm (n = 40) will receive routine care. We will document how feasible it will be to recruit and retain participants over 24 weeks and document the preliminary efficacy of the intervention on illness self-management, stigma, adherence to medications and severity of symptoms.

Data analysis: We will document the proportion of participants who consent and get recruited, the proportion of those who will get retained and reasons for drop out. We will conduct an intention to treat analysis comparing the groups at weeks 4, 12, 24 and assess the effect of the intervention on the clinical outcomes (described above). We will use the Bonferroni approach to correct for multiple comparisons.

Trial registration: Clinical trials.gov registration number: NCT04602585.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Harvey A Whiteford Louisa Degenhardt, Rehm Jürgen, Baxter Amanda J, Ferrari Alize J, Erskine Holly E, et al.. Global burden of disease attributable to mental and substance use disorders: fi ndings from the Global Burden of Disease Study 2010. The Lancet. 2013;10.1016/S0140-6736(13)61611-6
    1. Rössler W, Salize H.J, van Os J, A R-R. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15(4):399–409. doi: 10.1016/j.euroneuro.2005.04.009
    1. Jablensky Assen. Epidemiology of schizophrenia: The global burden of disease and disability. European Archives of Psychiatry and Clinical Neuroscience. 2000;250(6):274–85. doi: 10.1007/s004060070002
    1. Saarni Samuli I., Satu Viertiö Jonna Perälä, Koskinen Seppo, Jouko Lönnqvist, Suvisaari J. Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. Br J Psychiatry. 2010;197(5):386–94. doi: 10.1192/bjp.bp.109.076489
    1. Michalak Erin E, Yatham Lakshmi N, Lam Raymond W. Quality of life in bipolar disorder: A review of the literature. Health and Quality of Life Outcomes 2005;3(72): doi: 10.1186/1477-7525-3-72
    1. Laidia Charles, Prigentd A Alice Plasd, Leboyera Marion, Fond Guillaume, Chevreuld Karine, et al.. Factors associated with direct health carecosts in schizophrenia: Results from theFACE-SZ French dataset. European Neuropsychopharmacology. 2018;28:24–36. doi: 10.1016/j.euroneuro.2017.11.020
    1. Frey S. The economic burden of schizophrenia in Germany: A population-based retrospective cohort study using genetic matching. European Psychiatry. 2014;29(8):479–89. doi: 10.1016/j.eurpsy.2014.04.003
    1. Teferra Solomon, Shibre Teshome, Fekadu Abebaw, Medhin Girmay, Wakwoya Asfaw, Alem Atalay, et al.. Five-year mortality in a cohort of people with schizophrenia in Ethiopia. BMC Psychiatry,. 2011;11::165 doi: 10.1186/1471-244X-11-165
    1. Fekadu Abebaw, Medhin Girmay, Kebede Derege, Atalay Alem Excess mortality in severe mental illness: 10-year population-based cohort study in rural Ethiopia. The British Journal of Psychiatry. 2015;206:289–96. doi: 10.1192/bjp.bp.114.149112
    1. Simon Gregory E., Stewart Christine, Bobbi Jo Yarborough Frances Lynch, Coleman Karen J., Beck Arne, et al.. Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults. JAMA Psychiatry. 2018; doi: 10.1001/jamapsychiatry.2017.4437
    1. Ward Martha, Druss Benjamin. The epidemiology of diabetes in psychotic disorders. The Lancet Psychiatry. 2015;2(5): P431–51. doi: 10.1016/S2215-0366(15)00007-3
    1. Annamalai Aniyizhai, Kosir Urska, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes. 2017;8(8):390–6 doi: 10.4239/wjd.v8.i8.390
    1. Patel Vikram, Chatterji Somnath. Integrating Mental Health In Care For Noncommunicable Diseases: An Imperative For Person-Centered Care. HEALTH AFFAIRS. 2015;9:1498–505. doi: 10.1377/hlthaff.2015.0791
    1. Kiran Chandra, Chaudhury Suprakash. Prevalence of comorbid anxiety disorders in schizophrenia. Industrial Psychiatry Journal. 2016;25(1):35–40. doi: 10.4103/0972-6748.196045
    1. Buckley Peter F., Miller Brian J., Lehrer Douglas S., Castle David J. Psychiatric Comorbidities and Schizophrenia. Schizophrenia Bulletin 2009;35(2):383–402, 2009 doi: 10.1093/schbul/sbn135
    1. Hartz Sarah M., Pato Carlos N., Medeiros Helena, Patricia Cavazos-Rehg Janet L. Sobell, Knowles James A., et al.. Comorbidity of Severe Psychotic Disorders With Measures of Substance Use. JAMA Psychiatry. 2014;71(3):248–0. doi: 10.1001/jamapsychiatry.2013.3726 Published online January 1, 2014.
    1. Alem Atalay, Kebede Derege, Fekadu Abebaw, Shibre Teshome, Fekadu Daniel, Beyero Teferra, et al.. Clinical Course and Outcome of Schizophrenia in a Predominantly Treatment-Naive Cohort in Rural Ethiopia. Schizophrenia Bulletin. 2009;35(3):646–54 doi: 10.1093/schbul/sbn029
    1. Wilkinson P, Izmeth Z. Continuation and maintenance treatments for depression in older people. Cochrane Database of Systematic Reviews. 2016;(9):Art. No.: CD006727. doi: 10.1002/14651858.CD006727.pub3
    1. Shelton Richard C. Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy. Prim Care Companion J Clin Psychiatry. 2001;3(4):168–74. PMCID: PMC181183. doi: 10.4088/pcc.v03n0404
    1. Xia J, Merinder L.B, Belgamwar M.R. Psychoeducation for schizophrenia (Review). Cochrane Database of Systematic Reviews 2011;(6):Art. No.: CD002831. doi: 10.1002/14651858.CD002831.pub2
    1. Lene Halling Hastrup Christian Kronborg, Bertelsen Mette, Jeppesen Pia, Jorgensen Per, Petersen Lone, et al.. Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study). The British Journal of Psychiatry 2013;202:35–41. doi: 10.1192/bjp.bp.112.112300
    1. Ministry of Health of Uganda. Health Sector Development Plan (HSDP) 2015/16-2019/20. 2015.
    1. van der Ven E, Bourque F, Joober R, Selten J.P, Malla A.K. Comparing the clinical presentation of first-episode psychosis across different migrant and ethnic minority groups in Montreal, Quebec. Can J Psychiatry. 2012;57(5):300–8. doi: 10.1177/070674371205700505
    1. Brekke John S., Barrio Concepcion. Cross-Ethnic Symptom Differences in Schizophrenia: The Influence of Culture and Minority Status. Schizophrenia Bulletin. 1997;23(2):305–16. doi: 10.1093/schbul/23.2.305
    1. Cohen Alex, Padmavati Ramachandran, Hibben Maia, Oyewusi Samuel, John Sujit, Esan Oluyomi, et al.. Concepts of madness in diverse settings: a qualitative study from the INTREPID project. BMC Psychiatry 2016;16:388 doi: 10.1186/s12888-016-1090-4
    1. Njenga Frank. The concept of mental disorder: an African perspective. World Psychiatry. 2007;6(3):166–7.
    1. Teuton Joanna, Bentall Richard, Dowrick C. Conceptualizing Psychosis in Uganda The Perspective of Indigenous and Religious Healers. Transcultural Psychiatry. 2007;44(1):79–114 doi: 10.1177/1363461507074976
    1. Morgan Craig, Hibben Maia, Esan Oluyomi, John Sujit, Patel Vikram, Weiss Helen A., et al.. Searching for psychosis: INTREPID (1): systems for detecting untreated and first-episode cases of psychosis in diverse settings. Soc Psychiatry Psychiatr Epidemiol. 2015;50:879–93 doi: 10.1007/s00127-015-1013-6
    1. McGrath J. Dissecting the Heterogeneity of Schizophrenia Outcomes Schizophrenia Bulletin. 2008;34(2):247–8, 10.1093/schbul/sbm133
    1. Jongsma Hannah E., Charlotte Gayer-Anderson Antonio Lasalvia, Quattrone Diego, Alice Mulè Andrei Szöke, et al.. Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. JAMA Psychiatry. 2018;JAMA Psychiatry(75):1. doi: 10.1001/jamapsychiatry.2017.3554
    1. Jablensky A., Sartorius N., Ernberg G., Anker M., Korten A., Cooper J. E., et al.. Schizophrenia: manifestations, incidence and course in different cultures A World Health Organization Ten-Country Study. Psychological Medicine Monograph Supplement. 1992;20:1–97. doi: 10.1017/s0264180100000904
    1. Elliot M Goldner Lorena Hsu, Waraich Paul, Somers Julian M. Prevalence and Incidence Studies of Schizophrenic Disorders: A Systematic Review of the Literature. Can J Psychiatry. 2002;47:833–43. doi: 10.1177/070674370204700904
    1. Saha Sukanta, Chant David, Welham Joy, John McGrath. A Systematic Review of the Prevalence of Schizophrenia. PLoS Med. 2005;2(5):e141 doi: 10.1371/journal.pmed.0020141
    1. Emsley Robin, Chiliza Bonginkosi, Asmal Laila. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148(1–3):117–21. doi: 10.1016/j.schres.2013.05.016
    1. SDG 3: Ensure healthy lives and promote wellbeing for all at all ages [Internet]. 2020 [cited 21.02.2020].
    1. THE AFRICAN UNION COMMISSION. The Africa We Want A Shared Strategic Framework for Inclusive Growth and Sustainable Development FIRST TEN-YEAR IMPLEMENTATION PLAN 2014–2023,. 2015 21.02.2020. Report No.
    1. Uganda Ro. SECOND NATIONAL DEVELOPMENT PLAN 2015/16–2019/20 (NDPII) 2015.
    1. Breitborde NJK, Srihari VH, Woods SW. Review of the operational definition for first-episode psychosiseip. Early intervention in psychiatry. 2009;3(4):259–65. doi: 10.1111/j.1751-7893.2009.00148.x PMC4451818.
    1. Akena Dickens, Kiguba Ronald, Muhwezi Wilson W., Kwesiga Brendan, Kigozi Gwendolyne, Nakasujja Noeline, et al.. The effectiveness of a psycho-education intervention on mental health literacy in communities affected by the COVID-19 pandemic—a cluster randomized trial of 24 villages in central Uganda—a research protocol. BMC Trials. 2021; 22(446): doi: 10.1186/s13063-021-05391-6
    1. Sheehan D.V, Lecrubier Y, Harnett-Sheehan K. The Mini International Neuropsychiatric Interview (M.I.N.I.): The Development and Validation of a Structured Diagnostic Psychiatric Interview. J Clin Psychiatry. 1998;59:22–3.
    1. Emmanuel Kiiza Mwesiga Noeline Nakasujja, Nakku Juliet, Nanyonga Annet, Joy Louise Gumikiriza Paul Bangirana, et al.. One year prevalence of psychotic disorders among first treatment contact patients at the National Psychiatric Referral and Teaching Hospital in Uganda. Plos One. 2020;15(1):e0218843. doi: 10.1371/journal.pone.0218843
    1. Jeste D.V, Palmer B.W, Appelbaum P.S, Golshan S, Glorioso D, Dunn L.B, et al.. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry. 2007;64(8):966–74. doi: 10.1001/archpsyc.64.8.966
    1. Young R.C, Biggs J.T, Ziegler V.E, Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35. doi: 10.1192/bjp.133.5.429
    1. Kay Stanley R., Flszbeln Abraham, QpJer Lewis A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin. 1987;13(2):282–7.
    1. Mueser Kim, Gingerich S, Michelle Salyers, McGuire AB, Reyes R, Harry Cunningham. Illness Management and Recovery (IMR) Scales. Measuring the Promise: A Compendium of Recovery Measures. 2005;2:124–32. doi: 10.1037/t21500-000
    1. Graessel Elmar, Berth Hendrik, Lichte Thomas, Grau Hannes. Subjective caregiver burden: validity of the 10-item short version of the Burden Scale for Family Caregivers BSFC-s. BMC Geriatrics 2014;14:. doi: 10.1186/1471-2318-14-23
    1. Thompson K, Kulkarni J, Sergejew A.A. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;5(42):3. doi: 10.1016/s0920-9964(99)00130-9

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera